- E-posthalfdan.sorbye@uib.no
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- PostadressePostboks 78045020 Bergen
Vitenskapelig artikkel
- (2023). Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. Endocrine-Related Cancer. 12 sider.
- (2023). The effect of BRAF<sup>V600E</sup> mutation on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – A post-hoc exploratory analysis of the randomized NORDIC9-study. Journal of Geriatric Oncology.
- (2023). Takotsubosyndrom under behandling med fluorouracil. Tidsskrift for Den norske legeforening. 1-5.
- (2023). Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms. British Journal of Cancer.
- (2023). Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma. JCO Precision Oncology (JCO PO). 1-16.
- (2023). Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms. Journal of neuroendocrinology. 1-10.
- (2023). Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer. 12 sider.
- (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. Journal of neuroendocrinology.
- (2023). Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts. International Journal of Cancer. 488-503.
- (2022). Volumetric parameters from [18F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. Journal of neuroendocrinology. 16 sider.
- (2022). The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, dNLR, YKL-40, and IL-6) in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—The Randomized NORDIC9-Study. Journal of Clinical Medicine. 1-15.
- (2022). Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. The Oncologist. 299-306.
- (2022). Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. Cancer Treatment and Research Communications. 100517-100517.
- (2022). Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study. Journal of Geriatric Oncology. 1-9.
- (2022). Prognostic role of tumour infiltrating lymphocytes and macrophages in relation to tumour MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. British Journal of Cancer. 48-56.
- (2022). Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. Journal of neuroendocrinology. 9 sider.
- (2022). KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer. Frontiers in Oncology. 1-11.
- (2022). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. British Journal of Cancer. 726-735.
- (2022). Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. British Journal of Cancer. 2227-2233.
- (2022). Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open.
- (2021). Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut. 1768-1781.
- (2021). The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer. 1-14.
- (2021). Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. Journal of neuroendocrinology. 1-12.
- (2021). Quality of life in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—the randomized NORDIC9-study. Cancers. 16 sider.
- (2021). Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica. 931-941.
- (2021). Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. British Journal of Cancer.
- (2021). Feminizing adrenal tumor identified by plasma steroid profiling. Endocrinology, Diabetes and Metabolism Case Reports. 1-5.
- (2021). ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of neuroendocrinology. 1-10.
- (2021). Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. International Journal of Cancer. 1385-1397.
- (2020). Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology. 217-224.
- (2020). Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health and Quality of Life Outcomes. 1-11.
- (2020). PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLOS ONE. 1-12.
- (2020). Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncologica. 417-426.
- (2020). Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. Scientific Reports. 1-9.
- (2020). CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup . Frontiers in Oncology. 1-11.
- (2020). A plasma protein biomarker strategy for detection of small intestinal neuroendocrine tumors. Neuroendocrinology.
- (2020). A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology. 883-894.
- (2019). Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 54-62.
- (2019). Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology. 1088-1095.
- (2019). Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics. 1-14.
- (2019). Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology. 376-388.
- (2019). Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study. Endocrine-Related Cancer. 227-239.
- (2019). Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncologica. 1-8.
- (2019). Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. Cancer Medicine. 3623-3635.
- (2018). The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinology and metabolism clinics of North America (Print). 683-698.
- (2018). Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer. 1609-1616.
- (2018). Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology (MO).
- (2018). Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. British Journal of Surgery.
- (2018). Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer. 35-45.
- (2018). Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 807-815.
- (2017). Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv. 1-11.
- (2017). Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology. 1682-1689.
- (2017). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer.
- (2017). Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery. 580-589.
- (2017). Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial. BMC Surgery.
- (2017). High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLOS ONE. 1-13.
- (2017). Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer. 26-35.
- (2017). Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLOS ONE. 1-15.
- (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. Neuroendocrinology. 196-200.
- (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. Neuroendocrinology. 281-294.
- (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology. 266-280.
- (2017). Cetuximab in treatment of metastatic colorectal cancer: Final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer. 1271-1278.
- (2017). A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocrine-Related Cancer. 427-443.
- (2016). TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. OncoTarget. 59441-59457.
- (2016). Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. OncoTarget. 41948-41958.
- (2016). Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology. 1721-1728.
- (2016). NORDIC9: A randomized phase II trial exploring treatment of older patients with metastatic colorectal cancer (mCRC) by comparing full dose monotherapy (S-1 followed by irinotecan) with reduced combination regimen (S-1/oxaliplatin followed by S-1/irinotecan). Annals of Oncology. vi203.
- (2016). Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genetics. 22 sider.
- (2016). Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. OncoTarget. 75013-75022.
- (2016). Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer. 647-656.
- (2016). Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncologica. 881-885.
- (2016). ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 186-194.
- (2016). Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy. 12-22.
- (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
- (2015). Review on adjuvant chemotherapy for rectal cancer-why do treatment guidelines differ so much? Acta Oncologica. 437-446.
- (2015). Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. European Journal of Cancer. 2708-2717.
- (2015). Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World Journal of Surgical Oncology (WJSO).
- (2015). Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical decision making. 255-265.
- (2015). Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clinical colorectal cancer. 170-176.
- (2015). Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer. 2470-2477.
- (2015). High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLOS ONE.
- (2014). Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: Results from the NORDIC VII Study. PLOS ONE.
- (2014). Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica. 1284-1297.
- (2014). Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. European Journal of Cancer. 912-919.
- (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology. 152-160.
- (2013). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 1208-1215.
- (2013). Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Annals of Oncology. 2354-2360.
- (2012). Small Cell Lung Cancer in a 14-Year-Old Girl. Journal of Pediatric Hematology/Oncology. E86-E88.
- (2012). Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Annals of Surgery. 534-539.
- (2012). Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. Journal of Clinical Oncology. 1755-1762.
- (2012). Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. British Journal of Cancer. 189-194.
- (2012). Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. BMC Cancer.
- (2012). Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer. 435-441.
- (2012). Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine. 2189-2197.
- (2011). Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The Pharmacogenomics Journal. 61-71.
- (2011). Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 4617-4622.
- (2010). Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncologica. 740-756.
- (2009). Clinical Trial Enrollment, Patient Characteristics, and Survival Differences in Prospectively Registered Metastatic Colorectal Cancer Patients. Cancer. 4679-4687.
- (2008). Prognostic clinical factors in metastatic colorectal cancer. Advances in Gastrointestinal Cancers. 6-8.
- (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet. 1007-1016.
- (2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Annals of Oncology. 1154-1159.
- (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology. 909-914.
- (2005). SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
- (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
- (2004). Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
- (2003). Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
- (2003). Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
- (2003). Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
- (2002). Ulceration as a possible link between duodenogastric reflux and neoplasms in the stomach of rats. Journal of Surgical Research. 167-178.
- (2002). Gastric mucosa lesions induced by duodenogastric reflux increase the penetration of N-[3H]-methyl-N-nitro-N-nitrosoguanidine into the corpus mucosa of rats. Digestive Diseases and Sciences. 2354-2369.
- (2002). Duodenogastric reflux increases the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the antral mucosa of rats. A possible role for mucosal erosions and increased cell proliferation in gastric carsinogenesis. Japanese Journal of Cancer Research. 484-494.
- (2001). Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
- (1999). Glutathione modulation changes the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2063-2075.
- (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
- (1998). Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
- (1998). Effect of gastric secretion on the penetration of N-3H-methyl-N-nitro-N-nitrosoguanidine into the gastric mucosa of rats. Digestive Diseases and Sciences. 2012-2020.
- (1997). Glutathione and N-acetylcysteine reduce gastric mucosal blood flow in rats. Digestive Diseases and Sciences. 1765-1774.
- (1993). Gastric mucosal injury and associated changes in mucosal blood flow and gastric fluid secretion caused by dimethyl sulphoxide (DMSO) in rats. Digestive Diseases and Sciences. 1243-1250.
Rapport
- (2007). Health economic evaluation of bevacizumab for metastatic colorectal cancer. 23/2007. 23/2007. .
Vitenskapelig foredrag
- (2015). Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer.
- (2005). A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
Leder
- (2012). Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used? Acta Oncologica. 819-821.
Leserinnlegg
- (2019). Ekspertpanel for ny vurdering ved alvorlig sykdom. Tidsskrift for Den norske legeforening. 2 sider.
Short communication
- (2008). Surgery vs surgery and chemotherapy for colorectal liver metastases. The Lancet. 203.
Brev til redaktøren
- (2015). Reply to letter: "Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)". Annals of Surgery. e29.
Doktorgradsavhandling
- (2023). High-grade digestive neuroendocrine neoplasms. Impact of genetic alterations and morphologicalcharacteristics on outcome of first-line palliative chemotherapy.
- (1994). Penetration of carcinogens into normal and damaged gastric mucosa.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
- (2014). Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. 10 sider.
- (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. 4 sider.
- (2009). Endokrine svulster. 9 sider.
- (2008). The use of Chemotherapy for Neuroendocrine Tumors. 6 sider.
- (1999). Antimetabolitter. 20 sider.
Sammendrag/abstract
- (2022). Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients. Annals of Oncology. S955-S955.
- (2021). Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Annals of Oncology. S910-S911.
- (2021). Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carcinomas. Annals of Oncology. 915-915.
- (2019). Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Annals of Oncology. iv131-iv131.
- (2018). Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy. Annals of Oncology. v109-v109.
- (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
- (2013). Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3). Pancreas. 382-382.
- (2012). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. Journal of Clinical Oncology. 1 sider.
- (2012). Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study. Journal of Clinical Oncology. 1 sider.
- (2012). Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group. Journal of Clinical Oncology. 1 sider.
- (2012). Long term survival data from EORTC Study 40983:perioperative chemotherapy for resectable liver metastasesfrom colorectal cancer. Annals of Oncology. 18-18.
- (2012). EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Journal of Clinical Oncology. 1 sider.
- (2012). AGE DEPENDENT INCREASE IN MEDIAN AND LONG-TERM SURVIVAL IN 29 628 METASTATIC COLORECTAL CANCER (MCRC) SCANDINAVIAN PATIENTS DURING THE PAST TWO DECADES. Annals of Oncology. 188-188.
- (2010). Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic colorectal cancer biomodulation group. Annals of Oncology. 9-9.
- (2006). Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 146S-146S.
- (2005). Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. Journal of Clinical Oncology. 253S-253S.
Poster
- (2022). Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
- (2021). Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
- (2014). Development and validation of a Norwegian model for colorectal cancer.
- (2003). Nordic 5-fluorouracil/folinic acid bolus schedule combined with oxaliplatin (FLOX) as first-line treatment to metastatic colorectal cancer.
Errata
- (2016). Erratum: Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" (European Journal of Cancer (2016) 68 (208?209) (S0959804916320780) (10.1016/j.ejca.2016.04.010)). European Journal of Cancer. 208-209.
Vitenskapelig oversiktsartikkel/review
- (2023). Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Acta Oncologica. 431-437.
- (2023). Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment. Current Oncology Reports.
- (2020). PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocrine-Related Cancer. R67-R77.
- (2018). Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer. 115-124.
- (2016). Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer. 11-24.
- (2014). Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2814-2823.
- (2009). Positronemisjonstomografi ved nevroendokrine svulster. Tidsskrift for Den norske legeforening. 1474-1477.
- (2008). Palliativ kjemoterapi og strålebehandling ved metastatisk kolorectalkreft. Tidsskrift for Den norske legeforening. 194-197.